Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data PURPLE BIOTECH LTD. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.1
1
1
1
Research and development
4.18
4.64
5.27
2.28
7.24
11.8
16.3
17
7.62
3.73
Selling, general and administrative
3
6.4
5.2
4.39
6
6.11
6.28
5.24
3.18
3.25
General and administrative
3
6.33
1.04
1.89
1.53
Operating income
-7.18
-12
-7.83
-7.16
-12.6
-17.9
-22.6
-22.3
Interest expense
0.06
0.03
0.58
0.18
0.06
-0.21
0.07
2.2
0.48
0.98
Interest income
0.14
0.13
0.09
0.15
0.25
-0.32
0.91
0.99
0.87
0.42
Income tax
0.22
Income from continuing operations
-12.1
-12.9
-5.57
-5.41
28.7
17.8
21.8
20
7.28
26.5
Net income to minority interests
0.74
0.37
0.04
0.08
0.08
-0.09
-0.1
-0.04
-0.11
Net income
12.1
12.2
5.2
5.41
28.7
17.8
-21.7
-19.9
-7.24
-26.4
EPS, basic
0.00
0.00
0.00
0.00
0.00
23.29
23.97
17.96
4.44
0.03
EPS, diluted
0.00
0.00
0.00
0.00
0.00
23.29
23.97
17.96
4.99
0.03
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
6.76
3.95
5.16
4.39
11.2
10.9
15
14.5
7.4
8.72
Short-term investments
0.43
0.07
0.28
Total current assets
14.9
7.98
8.51
8.3
59.3
48.5
33.3
15.8
8.91
9.87
Property, plant and equipment
0.02
0.03
0.04
0.04
0.18
0.28
0.22
0.15
0.12
0.12
Lease right-of-use assets
0.21
0.79
0.62
0.47
0.32
0.16
0.22
Intangible assets
6.17
6.17
6.17
20.5
20.5
20.7
28
27.8
7.36
Total assets
14.9
14.2
14.7
14.7
83.8
70.2
54.6
44.3
37
17.6
Total current liabilities
1.27
3.97
3.31
3.55
3.1
4.25
7.06
9.7
3.99
7.75
Lease liabilities
0.03
0.69
0.55
0.32
0.16
Total liabilities
1.53
5.5
3.72
3.86
4.05
5.09
7.52
10
4.13
7.91
Paid-in capital
30.8
36
44.6
47
119
124
126
133
148
152
Retained earnings
-26.2
-38.5
-43.7
-49.5
-77.5
-95.9
-118
-137
-145
-171
Shareholders' equity
13.4
7.41
10.5
10.4
79.4
64.8
46.9
34.2
32.9
9.71
Minority interests
1.28
0.48
0.44
0.36
0.28
0.19
0.09
0.05
-0.06
Total equity
13.4
8.69
11
10.9
79.8
65.1
47.1
34.3
32.9
9.66
Total liabilities and equity
14.9
14.2
14.7
14.7
83.8
70.2
54.6
44.3
37
17.6
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
12.1
12.9
5.57
5.41
28.7
17.8
-21.8
-20
-7.28
-26.5
Stock-based compensation
0.66
1.15
1.05
Cash from operations
-6.26
-8.63
-8.48
-1.97
1.71
-0.37
-16.7
-19.9
-14.4
-5.66
Capital expenditures
-0.01
-0.01
-0.02
-0.01
-0.16
-0.12
-0.03
-0
-0
Cash from investing
-7.77
2.77
2.04
-0.45
-49.6
13.4
19.9
13.9
0.51
0.63
Debt issued
-0.02
Stock issued
6.29
2.42
4.68
2.59
27.9
0.56
1.5
1.56
5.81
3.15
Cash from financing
10.3
3
7.79
5.23
68.5
1.11
5.45
6.77
6.33
Exchange rate effect
-0.05
0.05
-0.14
0.02
0.06
-0.02
-0.15
0.05
-0
0.01
Net change in cash
-0.8
6.8
-0.33
4.29
-0.6
-7.08
1.31
Free cash flow
-6.27
-8.64
-8.5
-1.98
1.55
-0.49
-16.8
-19.9
-5.66
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $1.51 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-124.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-96.6%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
EPS growth, 1y
-99.5%
EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y
-89.6%
Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-70.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-40.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-34.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-52.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-31.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-26.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.27x
Current assets / current liabilities.
Quick ratio
1.12x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.12x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
$0.03
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$2.5M
Share price x shares outstanding.
Enterprise value
-$6.3M
Market cap + total debt - cash - short-term investments.
P/B
0.25x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.04x
Market cap / tangible book value, when positive.
FCF yield
-230.4%
Free cash flow / market cap.
Earnings yield
-1,074.0%
Net income / market cap (the inverse of P/E).
Was PURPLE BIOTECH LTD. profitable in fiscal 2025?
No. It reported a net loss of $26.4M.
How much free cash flow did PURPLE BIOTECH LTD. generate in fiscal 2025?
Cash from operations of $5.7M minus capital expenditures of $3.0K left free cash flow of -$5.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.